Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 13;41(9):2352–2365. doi: 10.1038/npp.2016.40

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 American College of Neuropsychopharmacology

PMC Copyright notice

Pretreatment with the dopamine receptor blocker caused a faster decline in 3,4-methylenedioxypyrovalerone (MDPV)-induced locomotor activity. Data are presented as mean±SE (n=6–8 rats per treatment). A significant main effect of drug treatment was observed for locomotor activity (F_3,24=11.8 p<0.0001; two-way analysis of variance (ANOVA) drug main factor × time repeated factor) and stereotypy (F_3,24=8.7, p=0.0004; two-way ANOVA drug main factor × time repeated factor). *, MDPV 3.0 mg/kg significantly different from saline; •, Flup+MDPV significantly different from saline; ○, MDPV 3.0 mg/kg significantly different from Flup+MDPV (Sidak's multiple comparison post hoc test, p<0.05). Flup, cis-flupenthixol.